News

News

Solasia Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho (PDF 121 KB)
Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2019) (PDF 306 KB)
Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2019 (under IFRS) (PDF 232 KB)
IR Report (Bridge Report) about Solasia
Solasia Announces Approval of episil® oral liquid in South Korea (PDF 165 KB)
Research report about Solasia was updated by Shared Research Inc.
Solasia Announces Development Strategy for Expanded Indication of PledOx and Amendment of License Agreement (PDF 196 KB)
Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma (PDF 106 KB)
Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2019) (PDF 276 KB)
Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2019 (under IFRS) (PDF 258 KB)
Solasia Launches episil® in China (PDF 268 KB)
Research report about Solasia was updated by Shared Research Inc.
Solasia Makes First Shipment of episil® (SP-03) to China (PDF 73 KB)
Sancuso® Newly Recommended in Guideline for Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies (PDF 249 KB)
Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2019) (PDF 230 KB)
Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2019 (under IFRS) (PDF 252 KB)
IR Report (Bridge Report) about Solasia
Research report about Solasia was updated by Shared Research Inc.
Notice of the Resolutions Adopted at the 11th Annual General Meeting of Shareholders (PDF 49 KB)
Solasia Launches Sancuso® in China (PDF 252 KB)
Solasia Files New Medical Device Application For episil® in South Korea (PDF 135 KB)
Notice of the 11th Annual General Meeting of Shareholders (PDF 466 KB)
Announcement Regarding Reduction in Amounts of Capital Stock and Legal Capital Surplus and Appropriation of Surplus (Deficit disposition of Retained earnings brought forward) and Election of Directors and Auditors (PDF 206 KB)
Rapid relief of pain in oral mucositis, New episil® oral liquid approved in China (PDF 197 KB)
Business Overview of Pipeline Products (Consolidated Financial Results for the Fiscal Year Ended December 31, 2018) (PDF 360 KB)
Consolidated Financial Results for the Fiscal Year Ended December 31, 2018 (under IFRS) (PDF 257 KB)
Notice of Review Progress of episil® oral liquid in China (PDF 157 KB)

Information for use of our products

The site you are about to access is intended to provide information for medical professionals in Japan. It is designed to allow users to better understand Solasia's products.

I have read and understood above

Page Top

SELECT YOUR LANGUAGE